seralutinib

Gossamer Bio and Chiesi Group to collaborate in therapy for lung condition
Reuters
Mon, 05/6/24 - 11:35 am
Gossamer Bio
The Chiesi Group
seralutinib
PAH
pulmonary arterial hypertension
Gossamer cuts loose 25% of its staff, ties future to phase 3 trial of tarnished Merck rival
Fierce Biotech
Wed, 05/10/23 - 10:10 am
Gossamer Bio
layoffs
seralutinib
Merck
PAH
Gossamer's PAH Candidate Meets Primary Endpoint, Stumbles on Secondary Measure
BioSpace
Tue, 12/6/22 - 08:58 pm
Gosamer Bio
PAH
seralutinib